Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$250.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

UMN Pharma Inc and Astellas Pharma Inc announces summary results in phase III clinical trials of seasonal flu vaccine ASP7374


Wednesday, 15 Jan 2014 01:30am EST 

UMN Pharma Inc and Astellas Pharma Inc:Says the summary results for two Phase III clinical trials of the recombinant seasonal influenza HA vaccine ASP7374.Says one of these clinical trials enrolled 900 healthy volunteers aged from 20 to 64 years to compare the immunogenicity and safety of subcutaneously-administered ASP7374 with approved egg-derived trivalent inactivated vaccine as well as non-inferiority of ASP7374 to the egg-derived vaccine.Says this clinical trial showed non-inferiority of the recombinant seasonal influenza HA vaccine ASP7374 in comparison with the egg-based vaccine in terms of immunogenicity, and no major safety problem was observed in ASP7374.Says another clinical trial enrolled 55 healthy volunteers aged 61 and over to evaluate the immunogenicity and safety of intramuscularly-administered ASP7374.Says this clinical trial showed favorable immunogenicity with no major safety problem observed in ASP7374. 

Company Quote

3485.0
-235.0 -6.32%
10:30pm EDT